Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04667234 | Expanded Access of Sotorasib | no longer available | — | — | AmgenINDUSTRY | 6 | Aug 20, 2026 | clinicaltrials |
| NCT05100134 | Managed Access Programs for LDK378, Ceritinib | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 1, 2026 | clinicaltrials |
| NCT04741789 |
| Managed Access Programs for INC280, Capmatinib |
| no longer available |
| — |
| — |
| Novartis PharmaceuticalsINDUSTRY |
| 0 |
| Mar 16, 2026 |
| clinicaltrials |
| NCT06841874 | Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC(Tale EAP) | no longer available | — | — | Nuvation Bio Inc.INDUSTRY | 0 | Dec 24, 2025 | clinicaltrials |
| NCT05225259 | Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Feb 28, 2024 | clinicaltrials |
| NCT02475382 | Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen(CheckMate 169) | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 2 | Nov 27, 2020 | clinicaltrials |
| NCT01947608 | Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 10 | Nov 3, 2020 | clinicaltrials |
| NCT03554434 | An Expanded Access Program for AM0010 (Pegilodecakin) | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Mar 2, 2020 | clinicaltrials |
| NCT02547675 | Rociletinib (CO-1686) USA Expanded Access Program | no longer available | — | — | Clovis Oncology, Inc.INDUSTRY | 1 | Sep 25, 2018 | clinicaltrials |
| NCT02784158 | An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer | no longer available | — | — | Ariad PharmaceuticalsINDUSTRY | 1 | Feb 6, 2018 | clinicaltrials |
| NCT02824094 | Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC | no longer available | — | — | PfizerINDUSTRY | 1 | Jul 21, 2017 | clinicaltrials |
| NCT01279798 | Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L) | no longer available | — | — | NovaRx CorporationINDUSTRY | 1 | Mar 1, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Aug 20, 2026source: clinicaltrials